Cannabidiol (CBD) triggered programmed cell death and disrupted cell-cycle progression in human fibrosarcoma cells, according to a study published online by the Journal of Cannabis Research. CBD reduced metabolic activity in both the cancerous and noncancerous cells in a dose-dependent manner, producing similar half-maximal inhibitory concentrations of 28.95 micromoles in fibrosarcoma cells and 30.75 micromoles in noncancerous fibroblasts. CBD reduced FAM111B gene expression in both cell types, but significantly reduced FAM111B protein levels only in the fibrosarcoma cells. The proportion of fibrosarcoma cells undergoing apoptosis increased from 3.55% in the untreated control group to 13.2% following CBD treatment. CBD also caused pronounced changes in the fibrosarcoma cells’ progression through the cell cycle.